Journal Article

No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer

Alison M. Dunning, Simon McBride, Jane Gregory, Francine Durocher, Nicola A. Foster, Catherine S. Healey, Neil Smith, Paul D. P. Pharoah, Robert N. Luben, Douglas F. Easton and Bruce A. J. Ponder

in Carcinogenesis

Volume 20, issue 11, pages 2131-2135
Published in print November 1999 | ISSN: 0143-3334
Published online November 1999 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/20.11.2131
No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

Endogenous hormone exposure is known to alter breast cancer susceptibility and genes responsive to such hormones are plausible candidates for predisposition genes. We have examined polymorphisms in genes for two members of the nuclear receptor superfamily which are expressed in breast tissue and known to moderate rates of cell proliferation in a case–control association study: the androgen receptor (AR) and the vitamin D receptor (VDR). We have used two series of Caucasian female breast cancer cases, one incident and one prevalent, and compared both with two sets of matched controls from the East Anglian region of Britain. Since the results are similar in the two series we have combined them. The AR poly[Gly]n and poly[Gln]n tracts were genotyped in a total of 508 female breast cancer cases and 426 controls. The VDR TaqI polymorphism was analysed in 951 cases and 627 controls drawn from the same population series. There were no significant differences between cases and controls for either the AR or VDR polymorphisms. Compared with individuals with two short alleles (<22 repeats) of the AR poly[Gln]n tract, the odds ratios and 95% confidence intervals (95% CI) for individuals with one or two long alleles were 0.82 (95% CI 0.62–1.09) and 1.31 (95% CI 0.87–1.97), respectively. Heterozygotes and homozygotes for the VDR TaqI cutting site had odds ratios of 1.01 (95% CI 0.81–1.27) and 0.97 (95% CI 0.71–1.32), respectively. None of the AR or VDR polymorphisms investigated has a major effect on risk of breast cancer in the British population.

Keywords: AR, androgen receptor; l, long; PAR, population attributable risk; RFLP, restriction fragment length polymorphism; s, short; VDR, vitamin D receptor.

Journal Article.  3953 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.